By prompt, I am assuming you mean after a positive readout from the planned P3 PDD trial perhaps some time in 2023?
Others cogent with the multitude of details regarding the conduct of acceptable drug trials can more accurately project when the FDA approves blarcamesine. No matter, the data in the paper be validating and supportive.